Claims for Patent: 7,569,362

Summary for Patent: 7,569,362

Title:	Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
Abstract:	The invention provides a method of producing multiple polypeptides, such as antibodies or antibody fragments, in a eukaryotic cell using a single expression vector. The expression vector is engineered to comprise two or more expression cassettes under the control of a single promoter wherein the expression cassettes have splice sites which allow for their alternative splicing and expression as two or more independent gene products at a desired ratio. Use of the vector for the efficient expression of recombinant antibodies in eukaryotic host cells is disclosed as well as the use of such antibodies in diagnostic and therapeutic applications.
Inventor(s):	Prentice; Holly (Carlisle, MA)
Assignee:	Biogen Idec MA Inc. (Cambridge, MA)
Application Number:	11/079,933
Patent Claims:	1. An expression vector comprising, a promoter; a 5' UTR; a single splice donor; an intron; a first splice acceptor; a first exon encoding a first polypeptide; a second splice acceptor; and a second exon encoding a second polypeptide, wherein the promoter is operably linked to the first and second exon, wherein upon entry into a cell, said single splice donor splices with said first splice acceptor, forming a spliced transcript which permits translation of said first exon, and said second splice acceptor forming a spliced transcript which permits translation of said second exon, wherein said first or second splice acceptor, or both, comprise any one of the sequences selected from the group consisting of SEQ ID NOS: 1-28, and wherein said first polypeptide and said second polypeptide are expressed from said spliced transcripts. 2. The vector of claim 1, wherein the promoter is a CMV promoter. 3. The vector of claim 1, further comprising a polyadenylation signal operably linked to said first exon or second exon. 4. The vector of claim 1, wherein said vector further comprises one or more additional splice acceptor and additional exon encoding an additional polypeptide, wherein said one or more additional splice acceptor comprises any one of the sequences selected from the group consisting of SEQ ID NOS: 1-28, and wherein upon entry into a cell, said single splice donor splices with said additional splice acceptor, forming an additional spliced transcript which permits translation of said additional exon, and wherein said additional polypeptide is expressed from said additional spliced transcript. 5. The vector of claim 1, wherein said first or second exons or both encode a selectable marker. 6. The vector of claim 1, wherein said first and second polyp eptide form a multimer. 7. The vector of claim 6, wherein said multimeric protein is a heterodimer, a heterotrimer, or a heterotetramer. 8. The vector of claim 1, wherein said splice donor and said second splice acceptor are derived from CMV and said first splice acceptor comprises any one of the sequences selected from the group consisting of SEQ ID NOS: 1-28. 9. The vector of claim 1, wherein said vector is a viral vector. 10. The vector of claim 1 comprising SEQ ID NO: 29. 11. An isolated eukaryotic cell containing the vector of claim 1. 12. The isolated cell of claim 11, wherein the vector is integrated into the chromosomal DNA of said cell. 13. The isolated cell of claim 11, wherein the vector is episomal. 14. The isolated cell of claim 11, wherein said cell is a mammalian cell or a yeast cell. 15. The cell of claim 14, wherein said cell is selected from the group comprising: a baby hamster kidney cell, a fibroblast, a myeloma cell, an NS0 cell, a PER.C6 cell, or a Chinese Hamster Ovary (CHO) cell. 16. The cell of claim 15, wherein said cell is a Chinese Hamster Ovary (CHO) cell. 17. A method of producing polypeptides, the method comprising: (a) culturing a cell of claim 11 in a culture; and, (b) isolating said first polypeptide and said second polypeptide from the culture. 18. An expression vector comprising, a promoter; a 5' UTR; a single splice donor; an intron; a first splice acceptor; a first exon encoding a first antibody polypeptide or fragment thereof a second splice acceptor; and a second exon encoding a second antibody polypeptide or fragment thereof, wherein the promoter is operably linked to the first and second exon, wherein upon entry into a cell, said single splice donor splices with said first splice acceptor, forming a spliced transcript which permits translation of said first exon, and said second splice acceptor, forming a spliced transcript which permits translation of said second exon, wherein said first or said second splice acceptor, or both, comprise any one of the sequences selected from the group consisting of SEQ ID NOS: 1-28, and wherein said first antibody polypeptide or fragment thereof and said second antibody polypeptide or fragment thereof are expressed from said spliced transcripts and associate to form an antibody or antibody fragment. 19. The vector of claim 18, wherein said first exon or said second exon or both encode an antibody fragment. 20. The vector of claim 18, wherein said first polypeptide is an antibody heavy chain or a fragment thereof and said second polyp eptide is an antibody light chain or a fragment thereof. 21. The vector of claim 18, wherein said first polypeptide is an antibody light chain or a fragment thereof and said second polyp eptide is an antibody heavy chain or a fragment thereof. 22. The vector of claim 20, wherein the light or heavy chain or both is murine, chimeric, humanized, human or synthetic. 23. The vector of claim 21, wherein the light or heavy chain or both is murine, chimeric, humanized, human or synthetic. 24. The vector of claim 18, wherein said splice donor and said second splice acceptor are derived from CMV and said first splice acceptor comprises any one of the sequences selected from the group consisting of SEQ ID NOS: 1-28. 25. The vector of claim 18, wherein said vector is a viral vector. 26. The vector of claim 18, comprising SEQ ID NO: 29. 27. An isolated eukaryotic cell containing the vector of claim 18. 28. The isolated cell of claim 27, wherein said vector is integrated into the chromosomal DNA of said cell. 29. The isolated cell of claim 27, wherein said vector is episomal. 30. The isolated cell of claim 27, wherein said cell is a mammalian cell or a yeast cell. 31. The cell of claim 30, wherein said cell is selected from the group comprising: a baby hamster kidney cell, a fibroblast, a myeloma cell, an NS0 cell, a PER.C6 cell, or a Chinese Hamster Ovary (CHO) cell. 32. The cell of claim 31, wherein said cell is a Chinese Hamster Ovary (CHO) cell. 33. A method of producing antibodies or antibody fragments, the method comprising: (a) culturing a cell of claim 27 in a culture; and, (b) isolating said first antibody polypeptide or fragment thereof and said second antibody polypeptide or fragment thereof from the culture.

Details for Patent 7,569,362

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2024-03-15
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2024-03-15
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2024-03-15